Targeting beta2-adrenoceptors for neuroprotection after cerebral ischemia: is inhibition or stimulation best?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Potential benefits of therapeutic use of β2-adrenergic receptor agonists in neuroprotection and Parkinsonμs disease.Journal of immunology research · 2014
   Review
2. Neuroinflammation, neuroautoimmunity, and the co-morbidities of complex regional pain syndrome.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2013
   Review
3. Dose-effects of aorta-infused clenbuterol on spinal cord ischemia-reperfusion injury in rabbits.PloS one · 2013
   Article

Corrections and comments

• Comment on
  Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor.2009
• Comment on
  The effects of beta-adrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats.2009

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as